Impact of Serum Progesterone in Modified Natural Cycles and Stimulated Cycles on Ongoing Pregnancy Rate

NCT ID: NCT04259996

Last Updated: 2023-10-24

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 488 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2020-02-19
• Study Completion Date: 2023-07-01

Brief Summary

Prospective cohort unicentric study including infertile patients undergoing an embryo transfer in the context of natural or stimulated cycles and receiving luteal phase support with vaginal natural progesterone following the clinical practice in our clinic in IVIRMA Valencia, Spain.

Detailed Description

Progesterone as a promoter of endometrial maturation is essential for the process of embryo implantation. The transformation of the endometrium from a proliferative state to a receptive state depends on the adequate progesterone exposure of the endometrium. Therefore, in any assisted reproduction technique (ART) the management of the luteal phase with exogenous administered progesterone, aiming to achieve a receptive endometrial state, is an essential part of the therapy. This important part of infertility-treatment is called luteal phase support (LPS).

Currently, there is a scientific debate and research regarding the timing, the dose and route of administration of exogenous progesterone in ART cycles. For years, the administration of progesterone was based on a "one fits all"- concept, mainly driven from the doctors and patients' preference regarding dose, timing and route of administration of the exogenous progesterone. Due to the lack of solid and evidence-based knowledge, the LPS improving investigating LPS is of outmost importance.

Therefore, improving the LPS is continuously in the focus of research and investigation. Main objectives of those efforts are to clarify the optimal timing, dosage and route of administration of progesterone for every possible ART procedure, in order to improve therapy outcomes. Of special interest in this wide field is the management of LPS in embryo-transfer-cycles such as substituted cycles and modified natural cycles for frozen-thawed cycles, and in fresh embryo-transfers after stimulated cycles.

Measuring serum progesterone levels in the luteal phase of a transfer cycle seems to be a promising approach in resolving the former mentioned doubts. Now, research focuses on luteal-phase serum progesterone levels as a predictor of outcomes. The discovery of certain thresholds of progesterone levels in the serum would give us a handy tool for individualizing the LPS with the main objective to improve outcomes.

Previous studies could show that there exist certain thresholds of serum progesterone in substituted cycles that could be used as a predictor. Furthermore, the same group could show that modifying the dose and the route of administration in the sense of individualizing LPS can improve outcomes.

Considering those results, it remains to clarify if there also exist thresholds of serum progesterone in modified natural cycles and stimulated cycles and if it's possible to improve the results through individualization of LPS the same way as it has been shown for substituted cycles.

The intention of the present study is to carry out the determination of serum progesterone on the day of the embryo transfer to all those patients who are going to be subjected in IVIRMA Valencia to an embryo transfer in a modified natural cycle or a stimulated cycle.

Conditions

Infertility, Female

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

MODIFIED NATURAL CYCLE

The term 'modified natural cycle' refers to a natural cycle in which ovulation is triggered by exogenous hCG administration in order to provide optimal timing scheduling embryo transfer. In contrast to the natural cycle, the applied hCG may lead to a different luteal phase profile. Luteal phase support is common clinical practice in those cycles.

On the day of embryo transfer (ET), eligible patients being transferred one or two good quality embryos on day 5 of development according to the Spanish ASEBIR classification will be informed about the nature of the study, read the informed consent (IC) form and decide if entering into the study. After signing the IC form, a blood test will be performed in a time frame between 1 and 2 hours before the ET.

The only intervention will be a single determination of serum P and E2 levels immediately before the embryo transfer.

PROGESTERONE AND ESTRADIOL SERUM CONCENTRATION MEASUREMENT

Intervention Type: PROCEDURE

The only intervention will be a single determination of serum P and E2 levels immediately before the embryo transfer.

STIMULATED CYCLE

On the day of embryo transfer (ET), eligible patients being transferred one or two good quality embryos on day 5 of development according to the Spanish ASEBIR classification will be informed about the nature of the study, read the informed consent (IC) form and decide if entering into the study. After signing the IC form, a blood test will be performed in a time frame between 1 and 2 hours before the ET.

The only intervention will be a single determination of serum P and E2 levels immediately before the embryo transfer.

PROGESTERONE AND ESTRADIOL SERUM CONCENTRATION MEASUREMENT

Intervention Type: PROCEDURE

The only intervention will be a single determination of serum P and E2 levels immediately before the embryo transfer.

Interventions

PROGESTERONE AND ESTRADIOL SERUM CONCENTRATION MEASUREMENT

The only intervention will be a single determination of serum P and E2 levels immediately before the embryo transfer.

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• The subject must provide written informed consent prior to any study related procedures
• Women ≤50 years old
• BMI ≤ 40 kg/m2
• Adequate endometrial thickness (>6.5mm) and pattern (Triple A structure) in the proliferative phase
• Regular menstrual cycles

Exclusion Criteria

• Uterine Pathology, adnexal pathology
• Systemic diseases

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Instituto Valenciano de Infertilidad, IVI VALENCIA

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Elena Labarta, MD

Role: PRINCIPAL_INVESTIGATOR

IVIRMA VALENCIA

Locations

Instituto Valenciano de Infertilidad Spain

Valencia, , Spain

Countries

Spain

Other Identifiers

1907-VLC-075-EL

Identifier Type: -

Identifier Source: org_study_id